H. Michael Shepard

2012

In 2012, H. Michael Shepard earned a total compensation of $1.7M as Vice President and Chief Scientific Officer at Halozyme Therapeutics, a 153% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$41,715
Option Awards$318,540
Salary$309,000
Stock Awards$1,066,273
Other$9,551
Total$1,745,079

Shepard received $1.1M in stock awards, accounting for 61% of the total pay in 2012.

Shepard also received $41.7K in non-equity incentive plan, $318.5K in option awards, $309K in salary and $9.6K in other compensation.

Rankings

In 2012, H. Michael Shepard's compensation ranked 4,021st out of 11,487 executives tracked by ExecPay. In other words, Shepard earned more than 65.0% of executives.

ClassificationRankingPercentile
All
4,021
out of 11,487
65th
Division
Manufacturing
1,394
out of 4,253
67th
Major group
Chemicals And Allied Products
315
out of 1,198
74th
Industry group
Drugs
189
out of 920
80th
Industry
Biological Products, Except Diagnostic Substances
35
out of 160
78th
Source: SEC filing on April 7, 2014.

Shepard's colleagues

We found five more compensation records of executives who worked with H. Michael Shepard at Halozyme Therapeutics in 2012.

2012

Gregory Frost

Halozyme Therapeutics

Chief Executive Officer

2012

Kurt Gustafson

Halozyme Therapeutics

Chief Financial Officer

2012

James Shaffer

Halozyme Therapeutics

Former Vice President and Chief Commercial Officer

2012

Jean Liu

Halozyme Therapeutics

General Counsel

2012

David Ramsay

Halozyme Therapeutics

Chief Financial Officer

You may also like